Here's Why Exelixis (EXEL) is a Strong Growth Stock

Company Overview - Exelixis, Inc. is an oncology-focused biotechnology company based in Alameda, CA, specializing in the discovery, development, and commercialization of new drugs for difficult-to-treat cancers [11] - The company is leveraging investments, expertise, and strategic partnerships to target a growing range of tumor types and indications with its differentiated pipeline of small molecules, antibody-drug conjugates (ADCs), and other biotherapeutics [11] Investment Potential - Exelixis has a Zacks Rank of 3 (Hold) and a VGM Score of A, indicating a solid investment profile [12] - The company is particularly appealing to growth investors, with a Growth Style Score of B, forecasting a year-over-year earnings growth of 15.5% for the current fiscal year [12] - Seven analysts have revised their earnings estimates higher in the last 60 days for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.17 to$2.31 per share [12] - Exelixis has an average earnings surprise of 26.9%, further enhancing its attractiveness to investors [12] Conclusion - With a strong Zacks Rank and top-tier Growth and VGM Style Scores, Exelixis is recommended for investors' consideration [13]